Can Bladder Cancer Spread? Where and How It Happens

Bladder cancer can and does spread, though the majority of cases are caught while the tumor is still confined to the bladder’s inner lining. When spread occurs, it follows predictable routes: first into the muscular wall of the bladder, then to nearby lymph nodes, and eventually to distant organs such as bone, lungs, and liver. How far a tumor has traveled at the time of diagnosis is the single strongest predictor of survival, which makes understanding these pathways more than academic.

How Bladder Cancer Grows Beyond the Lining

The bladder wall has distinct layers, and a tumor’s depth within those layers determines its stage and behavior. Most newly diagnosed bladder cancers are “non-muscle-invasive,” meaning they sit within the innermost tissue and have not reached the thick muscle underneath. Somewhere between 5% and 20% of these superficial tumors eventually progress deeper into the muscle wall, a transition that dramatically raises the risk of spread to other parts of the body.¹

At the cellular level, this invasion depends on tumor cells losing the sticky connections that normally keep lining cells anchored in place. Researchers call this process the epithelial-mesenchymal transition, and it shows up across many cancer types. In bladder cancer specifically, loss of a protein called E-cadherin and increased activity of enzymes that dissolve surrounding tissue have been linked to worse outcomes.² Essentially, the cancer cells remodel themselves to become more mobile and more capable of burrowing through tissue barriers.³

Certain molecular markers appear to track with this shift. One study found that a protein called IFIT5 is expressed at higher levels in muscle-invasive bladder tumors compared to non-muscle-invasive ones, suggesting it plays a role in driving deeper invasion.⁴ These details matter because identifying the molecular switches involved in invasion is what opens the door to drugs that might block the process.

Lymph Nodes Are the First Stop

Once a bladder tumor has pushed through the muscle wall, its most common next destination is the surrounding lymph nodes. Bladder cancer spreads primarily through the lymphatic system rather than the bloodstream in its early metastatic stages.¹ In a study of patients with metastatic bladder cancer, lymph nodes were the most frequently involved site, seen in about 69% of cases.⁵

The specific nodes involved follow the bladder’s natural lymphatic drainage. Research using fluorescent dye injected during surgery has mapped the drainage route: lymph fluid from the bladder travels along the inferior vesical blood vessels to the internal iliac lymph nodes first, then to the obturator and external iliac nodes.⁶ The pathway can also extend upward to retroperitoneal nodes along the spine, depending on the tumor’s position in the bladder and whether prior surgery has rerouted the lymphatic channels.⁷

Knowing this geography matters for surgeons deciding how extensively to remove lymph nodes during a radical cystectomy. It also matters for radiologists interpreting scans: an enlarged internal iliac node is more suspicious than one farther from the expected drainage route.

Where Distant Metastases Show Up

When bladder cancer breaks free of the pelvis entirely, it tends to land in a handful of preferred organs. The frequency ranking is fairly consistent across large studies: lymph nodes first, followed by bone, lungs, liver, and the peritoneum.⁵ Each site carries its own implications for symptoms, treatment options, and prognosis.

Bone

Bone is the most commonly diagnosed site for distant metastasis. Roughly 5% of bladder cancer patients already have metastatic disease at the time of their initial diagnosis, and bone leads the list of distant sites involved.⁸ The prognosis drops sharply once bone is involved: one-year survival for bladder cancer patients overall is around 84%, but for those with bone metastases, it falls to about 21%.⁸

Bone metastases that are present at diagnosis (synchronous) are found in roughly 1.4% to 5.5% of patients, while another 30% to 40% of bone metastases develop later, after the primary tumor has been treated.⁹ The real burden here extends beyond survival statistics. Bone metastases frequently cause skeletal complications: fractures, spinal cord compression, and severe pain. The rate of these skeletal events ranges from about 39% to 68% in affected patients.⁹

Lungs

The lungs are the second or third most common distant landing site, depending on the study. Pulmonary metastases from bladder cancer can take several forms: scattered round nodules, a single mass, tiny diffuse nodules throughout the lung tissue, or even lesions within the airways themselves.¹⁰ In rare cases, lung nodules can develop hollow centers (cavitation), which is unusual enough that it can mimic infection or other conditions on imaging.¹ Pleural effusion, where fluid accumulates around the lungs, is another way the disease can manifest in the chest.¹⁰

Liver

Liver metastases are found in roughly a quarter of patients with metastatic bladder cancer and carry a particularly grim outlook.⁵ Among patients with disease at a single distant site, those with liver metastases fare worst, with an average survival of about seven months.¹¹ A Danish study of patients who did not receive systemic treatment confirmed that liver involvement was the strongest marker of poor survival, and that long-term survivors tended to have a lower overall tumor burden without liver disease.¹²

Peritoneum

Peritoneal spread is less widely discussed but more common than many clinicians historically assumed. When bladder tumors grow through the full thickness of the bladder wall, they can enter the sub-peritoneal space and then seed the lining of the abdominal cavity. One imaging study found peritoneal involvement in about 16% of metastatic cases.⁵ The routes of peritoneal seeding are varied: spread can go superiorly toward the front of the abdomen, posterolaterally, or both. In one study, about 70% of patients with peritoneal spread had abdominal wall involvement, and over half had tumor on the bowel or its supporting tissue.¹³ The concern here is that peritoneal disease is often understaged on imaging, discovered only during surgery or on closer review.

Unusual Destinations

While the organs above account for the overwhelming majority of metastases, bladder cancer cells can occasionally turn up in unexpected places. Brain metastases are rare but documented. In one reported case, a man developed a tumor in his cerebellum nine years after his bladder was removed for cancer, and the mass was confirmed as metastatic bladder cancer.¹⁴ Another case involved metastasis to both the brain and skeletal muscles of the thigh, which is exceedingly uncommon.¹⁵

Skin metastases, while rare, are perhaps the most visually alarming. Bladder cancer can reach the skin through the bloodstream, through lymphatic channels, or even through direct implantation during surgical procedures. The skin lesions are variable in appearance, resist treatment, and signal an aggressive disease course.¹⁶ The same patient who developed a cerebellar metastasis later grew multiple red nodules on his abdominal skin, also confirmed as metastatic bladder cancer, highlighting that these rare sites can appear sequentially years after the original diagnosis.¹⁴

Histologic Subtypes That Spread Differently

Not all bladder cancers are created equal when it comes to spread. The vast majority are urothelial carcinomas (also called transitional cell carcinomas), but within that umbrella there are variant subtypes with distinct behaviors. The micropapillary variant, for instance, tends to present at a higher stage and has a worse overall survival than conventional urothelial carcinoma. In one study, organ and lymph node metastases were frequently found in micropapillary cases, and the micropapillary pattern itself was often present within the metastatic lymph node tissue, confirming it as the driver of spread.¹⁷

The plasmacytoid variant has an especially notable predilection for peritoneal spread. In a series of 15 patients, a third had intraperitoneal metastasis at the time of cystectomy, seeding sites like the bowel surface, omentum, ovary, and the space in front of the rectum.¹⁸ Patients with atypical histologic features overall had a significantly higher rate of peritoneal metastasis compared to those with conventional-looking tumors.⁵ Recognizing these variants under the microscope has real implications because it changes the surveillance plan and sometimes the treatment approach.

Gender Differences in Where Bladder Cancer Lands

An interesting and underappreciated detail is that the preferred metastatic site differs between men and women. In men with metastatic bladder cancer, bone is the most common distant site, while in women, the lungs lead.¹⁹ The reasons for this are not fully worked out, but they may involve hormonal influences on the tumor microenvironment, anatomic differences in lymphatic drainage, or differences in the molecular profile of the tumors that develop in each sex.

The survival implications differ by sex as well. Men with lymph-node-only metastatic disease tend to have a better prognosis than men with visceral organ metastases. That same pattern does not hold as clearly for women.¹⁹ And when looking specifically at patients with lymph node metastasis, men fare better than women. These disparities suggest that a one-size-fits-all approach to managing metastatic bladder cancer may miss important differences in biology.

How Spread Gets Prepared Before Cancer Cells Even Arrive

One of the more striking discoveries in metastasis research is that tumors can prepare distant organs for the arrival of cancer cells long before those cells actually travel there. Bladder cancer cells release tiny membrane-bound packages called exosomes into the bloodstream. Research has shown that bladder-cancer-derived exosomes carrying specific signaling molecules (ErbB2 and CRK) can reach the lungs ahead of the tumor cells and trigger abnormal blood vessel growth, creating a hospitable landing zone.²⁰ In animal experiments, mice pre-exposed to these exosomes developed more lung metastases when bladder cancer cells were later introduced, because the cancer cells were essentially “trapped” alongside the exosomes in the lung tissue. This concept of premetastatic niche formation helps explain why metastases tend to cluster in certain organs rather than scattering randomly.

Can Surgery Itself Dislodge Cancer Cells?

A question patients sometimes ask, and one the research community has investigated, is whether the surgical procedure to remove a bladder tumor can inadvertently push cancer cells into the bloodstream. The answer appears to be yes, at least transiently. A study measuring circulating tumor cells during transurethral resection of bladder tumors found that in six out of seven patients who tested positive, the number of circulating cancer cells in the large vein draining the lower body was higher during the operation than before it.²¹ Whether this transient spike actually leads to distant metastases is harder to prove, and for most patients the benefit of removing the tumor far outweighs the theoretical risk. Still, the finding adds context to clinical decisions about perioperative systemic therapy.

Detecting Spread With Imaging

Once muscle invasion is confirmed, the next critical question is whether cancer has spread beyond the bladder. Standard CT scans are widely used, but PET/CT scanning with a radioactive glucose tracer can improve detection of metastatic deposits. A systematic review reported sensitivity around 89% and specificity around 82% for staging muscle-invasive bladder cancer and its metastases using PET/CT.²² Not every study has been so optimistic: one large study of over 200 patients found PET/CT detected extra-pelvic metastatic lesions with a sensitivity of only 54%, though it still outperformed CT alone at 41%.²² The practical takeaway is that adding a PET scan to conventional imaging improves the chances of catching spread outside the pelvis, but no single scan is perfect, and small deposits can still be missed.

Blood-Based Clues to Early Spread

A growing area of research aims to detect spread before it becomes visible on imaging, using blood tests that capture circulating tumor cells or fragments of tumor DNA floating in the bloodstream. These “liquid biopsy” approaches are still largely experimental for bladder cancer, but early results are promising for specific clinical scenarios. One study found that in patients with high-risk non-muscle-invasive bladder cancer who had undergone repeat tumor resection, the proportion of a certain type of small circulating tumor cell was dramatically different between those who later recurred and those who did not: about 71% of the total circulating tumor cells were small in the recurrence group, versus 16% in the non-recurrence group.²³

Work on circulating tumor DNA is similarly active, with researchers exploring its potential to detect minimal residual disease after surgery, predict treatment response, and monitor for recurrence.²⁴ None of these blood-based markers are part of routine clinical practice yet, but they represent a plausible near-future tool for catching spread earlier than current imaging allows.

Treatment Once Bladder Cancer Has Spread

For decades, platinum-based chemotherapy was the only systemic option for advanced or metastatic bladder cancer. It remains an important tool, but the landscape has shifted with the arrival of immune checkpoint inhibitors. These drugs work by blocking proteins that tumors use to evade the immune system, and they offer a different safety profile that makes them usable in patients too frail for aggressive chemotherapy.²⁵

The evidence for immunotherapy in this setting is nuanced. A Cochrane review pooling data from over 3,500 patients found that as a first-line treatment, immunotherapy alone probably had little to no effect on the risk of death compared to chemotherapy.²⁶ Its greatest value appears to be in patients who have already progressed on chemotherapy or who cannot tolerate it, contexts where older options had little to offer. Newer approaches combine immunotherapy with chemotherapy or use antibody-drug conjugates, and the field is evolving rapidly. A person diagnosed today faces a different treatment menu than someone diagnosed five years ago.

When Only a Few Sites Have Spread

An emerging concept in oncology is the “oligometastatic” state, where cancer has spread to only one or a few distant spots rather than being widely disseminated. For bladder cancer, this is a particularly active area of study because some patients with limited metastatic burden seem to benefit from aggressive local treatment of those few deposits, on top of systemic therapy. Retrospective data suggest that consolidative radiotherapy aimed at a small number of metastatic sites improved both overall survival and progression-free survival in selected patients, roughly halving the risk of death compared to systemic therapy alone.²⁷ The logic is that reducing the leftover tumor burden, and with it the number of circulating tumor cells feeding further spread, might make the systemic therapy work better.

The challenge is identifying which patients truly have limited disease and which have widespread microscopic spread that just has not shown up on scans yet. Definitions of “oligometastatic” vary across studies, and most of the supportive evidence comes from retrospective series rather than randomized trials. Still, the data are encouraging enough that prospective trials are underway, and the concept represents a meaningful shift from the older view that metastatic bladder cancer is uniformly incurable. For a patient with, say, one or two bone lesions and good overall health, a discussion about targeted radiation to those sites alongside systemic therapy is now a reasonable conversation to have with an oncology team.